ESGO 2022 Poster Presentation (IMAGE)

SOPHiA GENETICS SA

ESGO 2022 Poster Presentation

Caption

Clinical relevance evaluation of a novel homologous recombination deficiency CE-IVD decentralized solution that identifies ovarian cancer patients that could potentially benefit from PARP-inhibitors.

Credit

NA

Usage Restrictions

NA

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.